Newsroom

Sorted by: Latest

-

Samson Rock Capital LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....
-

Samson Rock Capital LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....
-

Ant Group 2025 Sustainability Report Highlights Record AI R&D Investment

HANGZHOU, China--(BUSINESS WIRE)--Ant Group's 2025 Sustainability Report disclosed a record R&D investment of USD 5.17 billion (RMB 35.03 billion) in 2025—the fifth straight year of growth—alongside AI-powered green computing breakthroughs that contributed to cutting operational carbon emissions by 55.32% year-on-year. These milestones reflect Ant Group's commitment to sustainable AI development. “Does technological advancement necessarily lead to shared prosperity? The answer lies not in t...
-

Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies

SEATTLE--(BUSINESS WIRE)--Vedana Therapeutics (“Vedana”), a biotechnology company developing next-generation therapies for migraine prevention, today emerged from stealth with $46 million in Series A financing. The financing was co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments. Vedana’s executive team, board, and advisors include leaders who discovered and developed multiple migraine therapies, including approved calci...
-

EoS Fitness Brings Reformer Pilates to the Gym Floor

DALLAS--(BUSINESS WIRE)--EoS Fitness is bringing reformer Pilates out of the boutique studio and onto the gym floor....
-

Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  City Of Goteborg Issue of SEK 650,000,000.00 Floating Rate Green Notes due September 2030 Series No GB45 Tranche 1 MTN ISSUE NAME. Our Ref. MU3765 ISIN Code. XS3184154394 TOTAL INTEREST AMT. CURRENCY CODE. SEK DAY BASIS. Actual/360 (A004) NUM OF DAYS. 92 INTEREST RATE. 2.755 PCT VALUE DATE. 18/09/2026 INTEREST PERIOD. 18/06/2026 TO 18/09/2026 SEK 4,576,361.11 POOL FACTOR. N/A...
-

Realize Capital Partners franchit une étape importante avec la clôture finale de son Fonds I

TORONTO--(BUSINESS WIRE)--Realize Capital Partners, gestionnaire de fonds pour le Fonds de finance sociale du gouvernement du Canada (FFS), a annoncé aujourd’hui la clôture finale du Realize Fund I, son fonds de fonds de financement mixte à impact, dont le capital total s’établit désormais à 276,7 millions de dollars, puisqu’il a recueilli 141,7 millions de capitaux privés en complément de l’investissement d’ancrage de 135 millions effectué par le gouvernement du Canada en 2023. Realize Capital...
-

Realize Capital Partners Announces Landmark Final Close of Fund I

TORONTO--(BUSINESS WIRE)--$276.7M Realize Fund I aims to strengthen Canadian resiliency by growing the social finance market...
-

Marathon Asset Management Ltd UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must...
-

Marathon Asset Management Ltd UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must...